ALK and neoplasm: We treated Eml4-Alk mice with the first-line clinical ALK inhibitor alectinib27 and monitored changes in pulmonary protease activity over a two-week treatment course that resulted in rapid and robust tumor regression (Fig. 2b, Fig. S2a, b).